ChemicalBook > CAS DataBase List > PI3K/HDAC Inhibitor

PI3K/HDAC Inhibitor

Product Name
PI3K/HDAC Inhibitor
CAS No.
1339928-25-4
Chemical Name
PI3K/HDAC Inhibitor
Synonyms
CS-767;CUDC-907;EOS-62197;FIMEPINOSTAT;CUDC-907 /CUDC907;PI3K/HDAC Inhibitor;PI3K/HDAC InhibitorI;Fimepinostat(CUDC-907);PI3K/HDAC Inhibitor(CUDC-907);CUDC-907 (PI3K/HDAC InhibitorI)
CBNumber
CB42645120
Molecular Formula
C23H24N8O4S
Formula Weight
508.55
MOL File
1339928-25-4.mol
More
Less

PI3K/HDAC Inhibitor Property

Density 
1.445±0.06 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
≥25.45 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
form 
solid
pka
7.77±0.10(Predicted)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H290May be corrosive to metals

H302Harmful if swallowed

H310Fatal in contact with skin

H314Causes severe skin burns and eye damage

Precautionary statements

P234Keep only in original container.

P262Do not get in eyes, on skin, or on clothing.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P330+P331IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.

P303+P361+P353IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.

P390Absorb spillage to prevent material damage.

P405Store locked up.

P406Store in corrosive resistant/… container with a resistant inner liner.

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
25651
Product name
CUDC-907
Purity
≥98%
Packaging
5mg
Price
$120
Updated
2024/03/01
Cayman Chemical
Product number
25651
Product name
CUDC-907
Purity
≥98%
Packaging
10mg
Price
$228
Updated
2024/03/01
Cayman Chemical
Product number
25651
Product name
CUDC-907
Purity
≥98%
Packaging
25mg
Price
$477
Updated
2024/03/01
Cayman Chemical
Product number
25651
Product name
CUDC-907
Purity
≥98%
Packaging
50mg
Price
$822
Updated
2024/03/01
TRC
Product number
C834510
Product name
CUDC-907
Packaging
50mg
Price
$1100
Updated
2021/12/16
More
Less

PI3K/HDAC Inhibitor Chemical Properties,Usage,Production

Uses

CUDC-907 is a dual PI3K and HDAC inhibitor. Studies have shown CUDC-907 is able to enhance antitumor activity when combined with standard of care agents in multiple myeloma and B cell lymphoma xenograft models.

Uses

CUDC-907 is a dual PI3K and HDAC inhibitor. Studies have shown CUDC-907 is able to enhance antitumor activity when combined with standard of care agents in multiple myeloma and B cell lymphoma xenogra ft models.

Biological Activity

cudc-907 is a dual-acting inhibitor of hdac and pi3k with ic50 values of 1.7/5.0/1.8/2.8 nm (hdac1/2/3/10) and 19/54/39 nm (pi3k).[1]the phosphoinositide 3-kinases (pi3ks) contain three classes of pi3k each with its own distinct lipid products and specific substrate. they are a family of lipid kinases that regulates a wide range of pathway by propagating intracellular signaling cascades. pi3k phosphorylates the 3’-oh group of phosphatidylinositols. this activated akt, the protein ser/thr-kinase, by recruiting them to the cell membrane. the pi3k/akt signaling pathway is critical in cancer, because it promotes cell growth and survival. the studies have proved that pi3k pathway plays an important role in cancer progression and treatment for lung cancers, breast cancer.[2, 3] histone deacetylases (hdacs) and histone acetyltransferases (hats) mediates the balance between histone deacetylation and acetylation. hdacs also regulate the acetylation status of signaling molecules, chaperones, and transcription factors that are non-histone proteins.[4]cudc-907 is a potent inhibitor of class i pi3k kinases and hdac classes i and ii enzymes. cudc-907 resulted in increase of acetylated histones and non-histone proteins such as tubulin and p53. cudc-907 also induced p21 protein in h460 cell lines. cudc-907 dose-dependently decreases phosphorylation of akt and its downstream targets, p70s6 and 4ebp-1 by inhibiting the pi3k pathway,, in h460 cells. cudc-907 were able to inhibit the activation of mek in cancer cell lines including nsclc h460 cells, breast cancer bt-474 cells and nsclc h1975 cells. cudc-907 suppresses the raf- mek-mapk signaling pathway through hdac inhibition. cudc-907 can also cause the decrease of both p-src) and p-src in rpmi-8226 multiple myeloma cells. cudc-907 induced cell-cycle arrest at g2–m phase at the dose of 1 μm for 24h.[1]cudc-907 inhibited growth of the tumor in daudi cancer cell xenografts dose-dependently. in a xenograft tumor model of dlbcl (su-dhl4 diffuselarge b-cell lymphoma) cudc-907 induced tumor regression after oral administration (100 mg/kg) or intravenous (50 mg/kg). cudc-907 also caused tumor stasis in nsclc cell xenografts [1].

Enzyme inhibitor

This orally available, dual-PI3K/HDAC inhibitor (FW = 508.55 g/mol; CAS 1339928-25-4); Solubility: 100 mg/mL DMSO; <1 mg/mL Water), known as N-hydroxy-2- ( ( (2- (6-methoxypyridin-3-yl) -4-morpholino- thieno[3,2-d]pyrimidin-6-yl) methyl) (methyl) amino) -pyrimidine-5-carbox- amide, targets the phosphatidylinositol 3-kinase PI3Kɑ, and histone deacetylases HDAC1, HDAC2, HDAC3 and HDAC10 with IC50 values of 19 nM, 1.7 nM, 5 nM, 1.8 nM and 2.8 nM, respectively. PI3K/HDAC Inhibitor I inhibits other PI3K isoforms such as PI3Kβ, PI3Kγ, PI3Kδ, PI3KɑH1047R and PI3KɑE545K with IC50 of 54 nM, 311 nM, 39 nM, 73 nM and 62 nM, respectively. [1] Bao, Wang, Qu, et al., American Association for Cancer Research Meeting, Chicago, Illinois, Poster # 3744.

target

PI3Kα

References

[1]. qian c, lai cj, bao r, wang dg, wang j, xu gx, atoyan r, qu h, yin l, samson m et al: cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. clin cancer res 2012, 18(15):4104-4113.
[2]. wong kk, engelman ja, cantley lc: targeting the pi3k signaling pathway in cancer. curr opin genet dev 2010, 20(1):87-90.
[3]. engelman ja: targeting pi3k signalling in cancer: opportunities, challenges and limitations. nat rev cancer 2009, 9(8):550-562.
[4]. kim hj, bae sc: histone deacetylase inhibitors: molecular mechanisms of action and

PI3K/HDAC Inhibitor Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

PI3K/HDAC Inhibitor Suppliers

Shanghai XingMo Biotechnology Co., Ltd.
Tel
13524779951
Fax
QQ: 2075692521
Email
2075692521@qq.com
Country
China
ProdList
309
Advantage
55
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2923
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Fax
+86-25-83453306
Email
info@chemlin.com.cn
Country
China
ProdList
17987
Advantage
64
Jinan Trio PharmaTech Co., Ltd.
Tel
+86 (531) 88811783
Fax
+86 (531) 55696010 QQ 1762738062
Email
sales@trio-pharmatech.com (International market)
Country
China
ProdList
1856
Advantage
62
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
Country
China
ProdList
4647
Advantage
58
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax
+86-27-87599188
Country
China
ProdList
1494
Advantage
55
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7553
Advantage
61
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
18521735133 18521732826;
Fax
021-50323701
Email
market@aladdin-e.com
Country
China
ProdList
25015
Advantage
65
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4863
Advantage
58
More
Less

View Lastest Price from PI3K/HDAC Inhibitor manufacturers

Career Henan Chemical Co
Product
PI3K/HDAC Inhibitor 1339928-25-4
Price
US $2.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
100kg
Release date
2018-12-24

1339928-25-4, PI3K/HDAC InhibitorRelated Search:


  • FIMEPINOSTAT
  • CUDC-907 (PI3K/HDAC InhibitorI)
  • CS-767
  • CUDC907;CUDC 907 (PI3K/HDAC INHIBITORI)
  • FIMEPINOSTAT;PI3K/HDAC INHIBITOR
  • PI3K/HDAC Inhibitor
  • CUDC-907
  • CUDC-907 /CUDC907
  • N-hydroxy-2-(((2-(6-methoxypyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamidemethanesulfonate
  • EOS-62197
  • N-Hydroxy-2-[[[2-(6-methoxypyridin-3-yl)-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl](methyl)amino]pyrimidine-5-carboxamide
  • N-hydroxy-2-(((2-(6-methoxypyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamide
  • N-Hydroxy-2-[[[2-(6-methoxypyridin-3-yl)-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl](methyl)amino]pyrimidine-5-carboxamide CUDC-907
  • PI3K/HDAC InhibitorI
  • Fimepinostat(CUDC-907)
  • 5-Pyrimidinecarboxamide, N-hydroxy-2-[[[2-(6-methoxy-3-pyridinyl)-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-6-yl]methyl]methylamino]-
  • PI3K/HDAC Inhibitor(CUDC-907)
  • PI3K HDAC Inhibitor CUDC-907 CUDC907
  • 1339928-25-4
  • C23H24N8O4S
  • Inhibitor
  • Inhibitors